Notes for P&L
All amounts in SEKm unless otherwise stated.
Note 28 Cash flow statement
|Adjustment for items not included in cash flow||2011/2012||2010/2011||2011/2012||2010/2011|
|Gain/loss on sale of operations and non-current assets||-1.0||-10.7||–||–|
|Change in pension liability||2.3||6.9||1.0||-0.4|
|Group contributions/dividends not paid||–||–||-210.0||-160.0|
|Change in other provisions and accrued items||2.8||7.3||–||–|
For the Group, interest received during the year totalled SEK 5.4 million (3.6), and interest paid was SEK 13.2 million (6.4). For the Parent Company, interest received during the year was SEK 37.0 million (29.8), and interest paid was SEK 21.5 million (6.2).
The following adjustments were made as a result of the value of assets and liabilities in companies acquired during the year, together with adjustments such as contingent considerations paid for acquisitions made in previous years:
|Cash and cash equivalents||33.8||102.4|
|Interest-bearing liabilities and provisions||-47.4||-69.3|
|Non-interest-bearing liabilities and provisions||-107.0||-169.1|
|Consideration paid 1)||-293.8||-375.2|
|Cash and cash equivalents in acquired companies||33.9||102.4|
|Effect on the Group’s cash and cash equivalents||-259.9||-272.8|
|1) The consideration paid includes a contingent consideration charged to the income statement in the amount of SEK -1.6 million and the purchase of non-controlling interests of SEK -3.0 million.|
|The following adjustments were made as a result of the value of assets and liabilities in companies disposed of during the year:|
|Cash and cash equivalents||-1.2||-0.9|
|Capital gain on sold companies||–||-10.0|
|Non-interest-bearing liabilities and provisions||0.7||3.3|
|Cash and cash equivalents in companies disposed of||-1.2||-0.9|
|Effect on the Group’s cash and cash equivalents||-0.5||10.6|
|In the financial year, Electra-Box Pharma AB, a subsidiary of Electra-Box Diagnostica AB, which is included in the Addtech Life Science business area, was disposed of.|
|Year’s acquisitions (disposals) of operations|
|Company||Country||Acquisition (disposal) date||Ownership, %||Acquisition (selling) price|
|Ramström Transmission AB||Sweden||01-10-2011||100||12.5|
|NDC (assets and liabilities)||Sweden||15-10-2011||–||1.5|
|Rollco Holding AB||Sweden||02-01-2012||100||91.3|
|BioNordika Holding AB||Sweden||26-01-2012||100||69.3|
|(Electra-Box Pharma AB)||(Sweden)||(30-01-2012)||(-52)||(-0.7)|
All businesses acquired during the year were consolidated in the accounts using the acquisition method.
Cash and cash equivalents in the cash flow statement consist of cash and bank balances. The same definition applied to determine cash and cash equivalents in the balance sheet was applied in the cash flow statement.